

(The Group/Subsidiary companies of
Audhataam Pharmaceuticals Pvt. Ltd.)

Shaping the Future of Pharmaceuticals



Manufacturer of
API's, KSM's, CDMO &
Specialty Chemicals

Pioneering innovation in Active Pharmaceutical Ingredients, Chieron/Glochem delivers advanced solutions to meet the evolving needs of global healthcare.

Our expertise drives quality and excellence, ensuring a healthier future for all.



TRUSTED
by global
regulators

INNOVATIVE
portfolio
expansion

COMMITMENT
to excellence

Through the times

2025

Transition from Venkata Narayana Active Ingredients Pvt Ltd (VNAI) — Chieron Active Ingredients Pvt Ltd (CAI)

Successfully completed PMDA audit in May 2025

6 more products are under filing

Acquired Glochem Industries Pvt. Ltd.

Successful WHO GMP audit in July 2025 and USFDA in 2024

2024

- CEP approval received for 2 APIs
- ECOVADIS (application/certification)
- Awarded by golden peacock for sustainability
- Applied for PSCI membership
- Achieved B rating in CDP

2023

- China approval
- First filing in CADIFA, Brazil - Olmesartan filed

2020

State-of-the-art production block-2

2017-19

USFDA site approval I & II

2016

Achieved zero liquid discharge

2015

EDQM approval

2011

KFDA approval

2010

WHO GMP & ISO- 9001 certified

2008-09

First DMFs filed

2007

Start of operations

"Delivering best quality and cost leadership in supply of intermediates & APIs to the customers globally & achieving highest customer satisfaction"

Integrated Approach



01
APIs – Generics
& Innovator
Programs



02
CDMO/CMO –
APIs, Intermediates,
KSMs & RSMs



03
Specialty Chemicals – Contrast
Media, Nutraceuticals &
Electronic chemicals



04
CRO –
FTE Model

Approximately 80,000 Sq. Meters of land is available, and dedicated blocks for CMO activities can be built under partnership module backward Integration leads to cost competitiveness / supply reliability and quality control

Backward Integration leads to cost competitiveness / supply reliability and quality control



No. of
US DMFs filed **13**

Under filing
(FY'25-26) **06**

No. of
CEPs filed **08**

Under filing
(FY'25-26) **07**

No. of
US DMFs filed **08**

Under filing
(FY'25-26) **03**

No. of CEPs
approved **11**

Under filing
(FY'25-26) **03**

Production block highlights

Particulars		
		
Total site area	169,400 m ² (*An additional 50,000 m ² is available for setting up new production blocks)	15135 m ²
Total capacity	350 KL (addition of 50 KL (existing block & new 150 KL block under finalization))	96 KL
Block details	2 blocks (PB1 & PB2)	5 blocks (PB1, PB2, PB4, PB5, PB6)
Solvent recovery plant (SRP) equipment capacity	15 KL	10 KL
Effluent treated plant (ETP) equipment capacity -	100 KL	75 KL
Number of clean rooms	6 in number, all are class 100,000 (ISO-8) certified.	3 in number, all are class 100,000 (ISO-8) certified.

Equipment Details		
		
Total reactors	41	46
Dryers	10	15
Reactors SSR GLR	38	38
	21	8
Size reduction equipment's	07	12

Research & development capabilities

Scientific, diversified & technical Expert team

Ability to design robust, reproducible, and scalable synthetic routes.

Innovation & Intellectual Property (IP) Creation

Proven ability to move from lab to kilo lab to pilot plant to commercial scale efficiently.

Ensuring technology transfer packages are complete, reproducible, and compliant.

The API R&D Department's key strengths lie in its scientific excellence, IP-driven innovation, scalable process design, regulatory compliance, and cross-functional collaboration, enabling companies to deliver cost-effective, high-quality, and globally competitive APIs.

THREE R&D's facilities together with 18,000 sq.ft. built up area.

100+ Scientific team along with 20+ PhDs

Five synthesis labs with walk-in fume hoods & Four analytical labs with all sophisticated instruments

Kilo Lab, Pilot Plant & Commercial plant to cater gm scale to ton scale requirements



Strengthening safety culture & EHS excellence

“At Chieron and Glochem, ESG is not just a framework—it’s our foundation for building a resilient, responsible, and future-ready pharmaceutical company”

Top Priorities

- Drive safety from top management and CFT-HODs.
- ESG culture – LEAD Framework
- Launch “Safety champion” and “Star safety” awards.
- Prioritize ECOVADIS and BSC compliance for H1.



ecovadis



SCIENCE
BASED
TARGETS



- Installed Zero Liquid Discharge System (ZLD) Effluent Treatment Plant (ETP), Circular Disc Reverse
- Osmosis (CDRO), Multiple Effect Evaporation (MEE) and ATFD.
- Installed solar energy plant having capacity up to 2500 KW.
- Installed multi-stage scrubber system to control the fumes from various reactions.

**Environment
management system
ISO 14001**

**Occupational health &
safety management
system ISO 45001**

**Information security
management system
ISO/IEC 27001**

Energy
management
system
ISO 50001

Anti-Bribery
management
system
ISO 37001

Audit
conducted
and certificate
awaited





Resourceful solutions,
reliable results



Our Global Footprint




All over the globe including US, Europe, Japan,
China, Korea, Brazil, and other ROW markets



“ Focus on producing quality APIs, intermediates, and speciality chemicals prioritizing clean and green chemistry.



Pull out. explore. partner.





SCAN TO DOWNLOAD THE BROCHURE



— MANUFACTURING FACILITY ADDRESS —



Sy. No. 69, Chandrapadiya Village,
Vinjamur Mandal, Nellore District - 524 228



Plot #6/2&3, Sy.No. 174 & 176,
Industrial Development Area Bollaram,
Hyderabad, Telangana - 502 325

— OFFICE ADDRESS —

► HYDERABAD ◄

3rd floor, NCC building,
Vittal Rao Nagar, Hitech city, Madhapur,
Hyderabad 500 081

► MUMBAI ◄

20th floor, Tower 2, Unit No. 2001,
One International Center, Senapati Bapat
Marg, Mumbai - 400 013, Maharashtra, India.

► BANGALORE ◄

91 Spring board business hub private limited, 5th
floor, 175, and 176 dollars colony, phase 4, JP Nagar,
Bannerghatta Main road, Bengaluru - 560076

► AHMEDABAD R&D CENTRE ◄

Plot No. C-10, Akshar Industrial Estate, Sarkhej-Bavla Road,
Vasana-Chacharwadi, nearby Zydus Life Sciences, Changodar,
Ahmedabad, Gujarat - 382213.

E-mail: sunita@chieron.com, harish@chieron.com

*# Product Exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer sale in territories where it is not permitted by law. In USA products that are currently on patent are available for Research & Development use only in Accordance with 35 USC §271(e)(1). The Buyer is fully responsible for any legal action for launch in his country.

www.chieron.com

API - Commercial

Chieron Products

S.No.	API	USDMF	CEP	JDMF	KDMF	CADIFA	CDMF	Therapeutic Use
1	AIPAU	-	-	√	√	-	-	-
2	Benfotiamine	-	-	-	-	-	-	Vitamin supplement
3	Dapagliflozin Propanediol	√	√	-	-	-	-	Anti diabetic
4	Lacosamide	√	√	√	√	√	A Status	Anti convulsant
5	Levetiracetam	√	√	√	√	√	A Status	Anti convulsant
6	Linagliptin	√	EDMF	-	-	√	√	Anti diabetic
7	Loxoprofen Acid / Sodium	-	-	-	-	-	-	Anti inflammation
8	Oltmesartan Medoxomil	√	√	√	√	√	√	Anti hypertensive
9	Oseltamavir Phosphate	-	-	-	-	-	-	Anti viral
10	Quetiapine Fumarate	-	-	-	-	-	-	Anti psychotic
11	Risperidone	√	√	√	√	√	√	Anti psychotic
12	Rivaroxaban	√	√	-	-	-	-	Anticoagulant
13	Sitagliptin Phosphate (Chemical)	√	√	-	-	-	-	Anti diabetic
14	Sitagliptin Phosphate (Enzymatic)	√	√	-	-	-	-	Anti diabetic
15	Tetracaine Base / HCL	√	√	-	-	√	√	Anaesthetic
16	Vildagliptin	√	-	-	-	-	-	Anti diabetic
17	Warfarin S Amorphous	√	√	-	-	-	-	Anti coagulant
18	Warfarin S Clathrate	√	√	-	-	-	√	Anti coagulant

Glochem Products

S.No.	API	USDMF	CEP	JDMF	KDMF	CDMF	CADIFA	CA	RU	AU	Therapeutic Use
1	Amlodipine besylate (P-I)	√	√	√	√	√	√	√	√	√	Anti hypertensive
2	Amlodipine besylate (P-III)	√	√	√	√	√	-	√	-	-	Anti hypertensive
3	S(-) Amlodipine Besilate	√	√	√	√	√	-	√	-	-	Anti hypertensive
4	Amlodipine Maleate	-	√	-	-	√	-	-	-	-	Anti hypertensive
5	Amlodipine Phthalimido	-	√	-	√	√	-	-	-	-	Anti hypertensive
6	Cetirizine Dihydrochloride	√	√	-	√	√	√	-	-	-	Anti histaminic
7	Levocetirizine Dihydrochloride	√	√	√	√	√	√	-	-	-	Anti histamines
8	Hydroxyzine hydrochloride	√	√	-	-	√	√	-	-	-	Anti histaminic
9	Raloxifene Hydrochloride	√	√	-	-	-	-	√	-	-	Anti osteoporotic
10	Telmisartan	√	√	-	-	-	-	-	-	-	Anti hypertensive

Products Under Development

Chieron Products

Azilsartan medoxomil Potassium	Eprazinone dihydrochloride	Ezetimibe
Methylphenidate	Nebivolol hydrochloride	Pelubiprofen
Tegoprazan	Vonoprazan Fumarate	Zonisamide

Glochem Products

Bilastine	Famotidine	Lercanidipine
-----------	------------	---------------

API - Under Evaluation

Product Name		
Allopurinol	Alogliptin Benzoate	Betrixaban
Blarcamesine	Chlorpromazine HCL	Clobenzorex
Darolutamide	Elafibranor	Eluxadoline
Emricasan	Epacadostat	Evenamide
Fexuprazan	Hyaluronic acid	Lasmiditan
Lumateperone	Mavacamten	Mirogabalin
Omarigliptin	Quinfamide	Resmetirom
Tofisopam	Troriluzole	

Intermediates & KSMs

Chieron Products

S.No.	Products/Intermediates	CAS No	Products
1	4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one	91526-18-0	Azilsartan medoxomil
2	Methyl 1-[(2'-Cyano-[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate	139481-44-0	Azilsartan medoxomil
3	Methyl 2-ethoxy-1-((2'-(N-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate	147403-65-4	Azilsartan medoxomil
4	Methyl 2-Ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)biphenyl-4-yl] methyl]benzimidazole-7-carboxylate	147403-52-9	Azilsartan medoxomil
5	2-Ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid // Azilsartan	147403-03-0	Azilsartan medoxomil
6	8-bromo-7-(but-2-ynyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (LG-I)	666816-98-4	Linagliptin
7	2-(4-(bromomethyl)phenyl) propanoic acid (BPP)	111128-12-2	Loxoprofen
8	Methyl Cyclopentanone-2-carboxylate (MCP)	10472-24-9	Loxoprofen
9	2-Phenyl-2-(Pyridine-2-yl)acetamide (PPA)	7251-52-7	Methylphenidate
10	Ritalinic Acid**	19395-41-6	Methylphenidate
11	2-Phenyl-2-(Piperidine-2-yl) acetamide (Mixture of Diastereomers)	19395-39-2	Methylphenidate
12	6-Fluoro-3,4-Dihydro-2H-benzopyran-2-Carboxylic acid	99199-60-7	Nebivolol HCl
13	(±)-[1R*(R*)]-6-Fluoro-3,4-Dihydro-2-Oxiranyl -2H-1-Benzopyran	876514-31-7	Nebivolol HCl
14	(±)-[1S*(R*)]-6-Fluoro-3,4-Dihydro-2-Oxiranyl-2H-1-Benzopyran	793669-26-8	Nebivolol HCl
15	rac N-Benzyl Nebivolol // BENL	929706-85-4	Nebivolol HCl
16	Trityl Olmesartan Medoxomil	144690-92-6	Olmesartan
17	Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate (Imidazole ester)	144689-93-0	Olmesartan
18	(1S,5R,6S)-Ethyl 5-(pentan-3-yloxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylate	204254-96-6	Oseltamivir

** USDMF filed

S.No.	Products/Intermediates	CAS No	Products
19	Ethyl (3R,4R,5S)- 4-(N-tert-butylacetamido)-5-(diallylamino)-3-(pentan-3-yloxy)-cyclohex-1-enecarboxylate hydrochloride	651324-08-2	Oseltamivir
20	Dibenzo[b,f] thiazepin-11(10H)-one	3159-07-7	Quetiapine Fumarate
21	1-[2-(2-Hydroxyethoxy)ethyl]Piperazine	13349-82-1	Quetiapine Fumarate
22	(R)-5-Chloro-N-(2-hydroxy-3-((4-(3-oxomorpholino)phenyl) amino)propyl)thiophene-2-carboxamide	721401-53-2	Rivaroxaban
23	1-(3-(Trifluoromethyl)-5,6-dihydro-[1,2,4] triazolo[4,3-a] pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butane-1,3-dione	764667-65-4	Sitagliptin
24	2-(2,4,5-trifluorophenyl)acetic acid	209995-38-0	Sitagliptin
25	3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a] pyrazine hydrochloride	762240-92-6	Sitagliptin
26	4-[[[(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl] oxy]-N,N,2-trimethyl-1-[(4-methylphenyl)sulfonyl]-1H-Benzimidazole-6-carboxamide	942485-42-9	Tegoprazan
27	(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-ol	942195-91-7	Tegoprazan
29	4-hydroxy-N,N,2-trimethyl-1-[(4-methylphenyl)sulfonyl]-1H-Benzimidazole-6-carboxamide	942195-86-0	Tegoprazan
30	N,N,2-trimethyl-1-[(4-methylphenyl) sulfonyl]-4-(phenylmethoxy)- 1H-Benzimidazole-6-carboxamide	942195-85-9	Tegoprazan
31	5-(2-Fluorophenyl)-1H-pyrrole-3-carboxaldehyde	881674-56-2	Vonoprazan Fumarate
32	5-(2-Fluorophenyl)-1-[(pyridin-3-yl)sulfonyl]-1H-pyrrole-3-carboxaldehyde	881677-11-8	Vonoprazan Fumarate
33	Ethyl 5-(2-fluorophenyl)-1H-pyrrole-3-carboxylate	881674-06-2	Vonoprazan Fumarate

Specialty Chemicals – OLED, Semiconductor & Contrast Media

Chieron Products

S.No.	Chemical Name	CAS No.	End Use
1	Iohexol	66108-95-0	Contrast Media
2	4-Chloro-2-iodoaniline	63069-48-7	Contrast Media
3	5-Nitro Isophthalic acid	618-88-2	Contrast Media
4	Iopamidol	60166-93-0	Contrast Media
5	5-Iodo-2-methylbenzoic acid	54811-38-0	Contrast Media
6	1,4,7,10-Tetraazacyclo dodecane	294-90-6	Contrast Media
7	10-(2-Hydroxypropyl)-1,4,7,10-tetraaza cyclododecane-1,4,7-triacetic acid	120041-08-9	Contrast Media
8	5-Amino-N,N'-bis(2,3-dihydroxypropyl) isophthalamide Hydrochloride	203515-86-0	Iohexol / Contrast media
9	Dimethyl-5-Nitroisophthalate	13290-96-5	Iohexol / Contrast media
10	5-Amino-2,4,6-Triiodoisophthaloyl Dichloride	37441-29-5	Iohexol / Contrast media
11	5-Amino-2,4,6-Triiodoisophthalic Acid	35453-19-1	Iohexol / Contrast media
12	(Pentamethylcyclopentadien-1-yl) trimethyl silane	87778-95-8	Electro Chemicals
13	4-(tert-butyl)-2phenylpyridine	53911-36-7	Electro Chemicals
14	(4,6-dihydroxy-1,3-phenylene)bis (phenyl methanone)	3088-15-1	Electro Chemicals
15	1H-1,2,3-triazolo-(4,5-b)- pyridine	273-34-7	Electro Chemicals
16	6-cyclopentyl-1-(3,5-dimethylphenyl) isoquinoline	2122870-54-4	Electro Chemicals
17	8,10-dibromo-3-(trifluoro methyl)-7,7-dimethyl-7H-benzo[c]fluoren-5-ol	1309957-29-6	Electro Chemicals
18	9-(trifluoromethyl)-2,3-dimethoxy-7, 7-dimethyl-7H-benzo[c]fluoren-5-ol	1021540-53-3	Electro Chemicals
19	1,1,1-trifluoro-, 2-(1,1-dimethylethyl) -3,6-dihydro-6-oxo-2H-pyran-4-yl ester Methane sulfonic acid	1020850-76-3	Electro Chemicals

S.No.	Chemical Name	CAS No.	End Use
20	1-(1-Methylethyl)cyclohexyl 2-methyl-2-propenoate (IPCHMA)	811440-77-4	Semiconductor
21	2-methyl-2-[(hexahydro-2-oxo-3, 5-methano-2H-cyclopenta [b]furan-6-yl) oxy]-2-oxoethyl ester, 2-Propenoic acid (ACNLM)	347886-81-1	Semiconductor
22	2-Ethyl-2-adamantyl methacrylate (EAdMA)	209982-56-9	Semiconductor
23	2-Methylacrylic Acid 2-Oxotetrahydrofuran-3-yl Ester (GBLMA)	195000-66-9	Semiconductor
24	1-Methyl-1-cyclopentyl Methacrylate (McPMA)	178889-45-7	Semiconductor
25	2-Methyl-2-adamantyl methacrylate (MAdMA)	177080-67-0	Semiconductor
26	3-Hydroxy-1-methacryloyl oxyadamantane (HMA)	115372-36-6	Semiconductor
27	1-(1-methylethyl)cyclopentyl 2-methyl-2-propenoate (IPCPMA)	1149760-04-2	Semiconductor
28	2-Iodobenzoic acid	88-67-5	Speciality Chemicals
29	Diiodomethane	75-11-6	Speciality Chemicals
30	1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide Hydrochloride(EDC-HCl)	25952-53-8	Speciality Chemicals

Product list - Nutraceutical

Chieron Products

S.No.	Chemical Name	CAS No.	End Use
1	Beta-Carotene 98% *	7235-40-7	Used as intermediates in food and pharma products
2	Calcium Orotate	22454-86-0	It may be used to treat conditions caused by low calcium levels such as Osteoporosis, Osteomalacia, decreased activity of the Hypoparathyroidism, and a certain muscle disease.
3	Curcumin (3 Peak) 95%		As Food Supplement
4	Hydantoin	461-72-3	KSM for many a-Ketoanalogue molecules
5	Lithium Orotate	5266-20-6	Low-dose lithium orotate boosts cognitive function, Boosting the Immune System, Relieves Headaches, Promotes Longevity and Anti-Aging,
6	Magnesium Orotate	34717-03-8	This medication is a mineral supplement used to prevent and treat low amounts of magnesium in the blood.
7	Orotic Acid Monohydrate	50887-69-9	KSM for Mg. Orotate, Ca. Orotate
8	Zinc Orotate	68399-76-8	increase the immune system function, healthy skin, hair and vision.